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Abstract
Background: Hydroxychloroquine (HCQ) retinopathy may be more common than previously recognized; recent
ophthalmology guidelines have revised recommendations from ideal body weight (IBW)-based dosing to actual
body weight (ABW)-based dosing. However, contemporary HCQ prescribing trends in the UK remain unknown.
Methods: We examined a UK general population database to investigate HCQ dosing between 2007 and 2016.
We studied trends of excess HCQ dosing per ophthalmology guidelines (defined by exceeding 6.5 mg/kg of IBW
and 5.0 mg/kg of ABW) and determined their independent predictors using multivariable logistic regression
analyses.
Results: Among 20,933 new HCQ users (78% female), the proportions of initial HCQ excess dosing declined
from 40% to 36% using IBW and 38% to 30% using ABW, between 2007 and 2016. Among these, 47% of
women were excess-dosed (multivariable OR 12.52; 95% CI 10.99–14.26) using IBW and 38% (multivariable OR
1.98; 95% CI,1.81–2.15) using ABW. Applying IBW, 37% of normal and 44% of obese patients were excess-
dosed; however, applying ABW, 53% of normal and 10% of obese patients were excess-dosed (multivariable
ORs = 1.61 and 0.1 (reference = normal); both p < 0.01). Long-term HCQ users showed similar excess dosing.
Conclusion: A substantial proportion of HCQ users in the UK, particularly women, may have excess HCQ
dosing per the previous or recent weight-based guidelines despite a modest decline in recent years. Over
half of normal-BMI individuals were excess-dosed per the latest guidelines. This implies the potential need to
reduce dosing for many patients but also calls for further research to establish unifying evidence-based safe
and effective dosing strategies.
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Background
Hydroxychloroquine (HCQ) is commonly prescribed in
patients with systemic lupus erythematosus (SLE) and
remains a cornerstone of lupus care today [1, 2], and it
is also often used in the management of rheumatoid
arthritis (RA) and other rheumatic conditions. Since the
landmark trial that showed HCQ discontinuation led to
a nearly threefold higher risk of lupus exacerbation [3],
many subsequent studies have reported wide-ranging
benefits of HCQ, including improved survival, reduced
disease activity and damage accumulation, and a lower
risk of pregnancy complications, venous thromboembol-
ism, dyslipidemia, and insulin resistance among patients
with SLE [4–7]. In RA, the efficacy of triple therapy
(which includes HCQ) is proven to be similar to that of
etanercept [8], while being much more cost-effective [9].
This profile will likely remain attractive worldwide, even
in the era of modern biologic agents.
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Although HCQ is generally well-tolerated, the major
long-term adverse event is vision-threatening toxic retinop-
athy [10, 11]. Rates of HCQ retinopathy were historically
considered low (< 2%) [12–15]. Previously, the 2009 Royal
College of Ophthalmologists (RCO) and 2011 American
Academy of Ophthalmology (AAO) guidelines each recom-
mended a maximum safe dose of 6.5 mg/kg/day of ideal
body weight (IBW) (up to a maximum of 400 mg daily) to
minimize the risk of retinopathy [2, 16, 17]. However, in
2016, the AAO updated their maximum daily dose recom-
mendation to 5 mg/kg/day actual body weight (ABW),
based largely on a retrospective study based in Kaiser
Permanente Northern California (KPNC) [18–20]. This
study utilized modern, sensitive screening methods that can
identify early stages of retinopathy and identified an overall
prevalence of HCQ retinopathy of 7.5%, over three times
higher than previous estimates [14, 21, 22]. The rate of ret-
inopathy was considerably higher with HCQ doses over
5.0 mg/kg ABW [18]. Following the KPNC study, there has
been renewed concern in the USA about the appropriate
dosing of HCQ, reflected in the latest AAO guidelines
[15, 19, 23, 24]. Despite the previous IBW-based recom-
mendation [16], there may have been less concern about
HCQ retinopathy in the UK than in the USA, as the RCO
had not recommended routine HCQ retinopathy screening
prior to 2017 [16, 25–27]. To that end, to what extent re-
cent HCQ prescriptions would exceed dosing recom-
mended by ophthalmology guidelines remain unknown.
To understand recent prescribing trends in the UK
and to elucidate the predictors of potential excess dos-
ing, we assessed HCQ prescribing patterns in relation to
the previous and latest HCQ dosing guidelines [16, 17,




Our study cohort was derived from The Health
Improvement Network (THIN), an electronic medical
record (EMR) database which represents 6.2% of the
UK population, including over 11 million patients.
THIN database is representative of the general UK
population in terms of demographics, lifestyle factors,
and healthcare utilization [28]. Healthcare information
includes general practitioner visits, specialist referrals,
diagnoses from hospital admissions and specialists,
medications, and laboratory results. The specific diag-
noses are recorded by the Read code classification
system, which is the standard nomenclature of clinical
terms used by the National Health Service in describ-
ing clinical diagnoses [29]. Medication prescriptions
are recorded by the Multifunctional Standardized
Lexicon for European Community Language (MULTI-
LEX) classification system [30].
Study population and design
We identified all subjects age 18 years or older within
THIN with incident HCQ prescriptions between 1
January 2007 and 31 December 2016. We divided these
cohorts into five 2-year blocks each, based on index
date, determined by the date of first documented HCQ
prescription. We required ≥1 year of subject inclusion in
THIN prior to the index date to be considered an inci-
dent prescription.
Assessment of covariates
We determined information from the most recent avail-
able data prior to the index date on age, sex, lifestyle
(i.e., smoking), and anthropometric characteristics (i.e.,
height and body weight). We calculated body mass index
(BMI) and IBW using the commonly used Devine for-
mula (for women, 45.5 kg + 2.3 × height in inches over
60 in. and for men, 50 kg + 2.3 × height in inches over
60 in.) [30, 31], as was also used in the recent KPNC
paper [18]. We identified the indication for HCQ use by
Read diagnosis codes. We also determined baseline
comorbidities (i.e., diabetes mellitus and chronic kidney
disease (CKD) stage ≥ 3) and medication use (i.e., tam-
oxifen, which has been previously implicated in
increased risk of HCQ retinopathy) [18].
Assessment of outcomes
We identified the incident HCQ prescription dose for
the primary analysis. We also obtained overall (incident
and renewal prescriptions) HCQ prescription dose,
assessing the first prescription dose in a given calendar
year for each subject. We classified the weight-based
excess HCQ dose according to recommended safe doses
per IBW (i.e., > 6.5 mg/kg) [16, 27], and per ABW (i.e.,
> 5.0 mg/kg) [18, 19]. We also examined HCQ daily dose
categories (i.e., 100 mg, 200 mg, 300 mg, 400 mg,
500 mg, and 600 mg), rounding to the nearest 100 mg
(or one half tablet) per day, given that this medication is
only available in 200 mg tablets.
To examine the dosing trends according to the dur-
ation of use, we obtained the initial HCQ prescription
dose and the HCQ prescription dose at 5 years of treat-
ment for a subgroup of subjects with at least 5 years of
HCQ use. We similarly classified their 1st and 5th year
prescription doses according to recommended doses per
ABW and IBW.
Statistical analysis
We compared the baseline characteristics of individuals
at the index date of their incident HCQ prescriptions
according to calendar year categories. We calculated the
proportion of incident HCQ prescriptions exceeding
either IBW or ABW maximum safe dose over the five
2-year cohort blocks and described the secular trends.
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We examined the relationship between age, sex, BMI,
CKD, and indication for HCQ use and the risk of
prescribed HCQ dose exceeding each safe dose for
IBW or ABW, respectively, using a multivariable lo-
gistic regression model. The final multivariable model
was adjusted for age, sex, BMI, CKD, indication for
HCQ use, smoking, tamoxifen use, diabetes mellitus,
and calendar year.
We calculated median and interquartile ranges for ini-
tial HCQ dose per IBW and ABW at 6-month intervals
between 2007 and 2016 and performed quantile regres-
sion to assess the median value trends. Furthermore, we
calculated the proportion of different HCQ dose cat-
egories (i.e., 600 mg, 500 mg, 400 mg, 300 mg, 200 mg,
and 100 mg) comprising overall initial HCQ doses over
this same timeframe. We also calculated the proportion
of these dose categories comprising overall (incident and
renewal) HCQ doses over this timeframe.
Results
During the 10-year period between 2007 and 2016, 20,933
individuals initiated HCQ (Table 1). The majority were fe-
male (78%). The mean age was 55.6 years and mean BMI
was 27.7 kg/m2. RA was the most common indication for
HCQ use (56%), 2257 subjects (11%) had SLE, and 1572
(8%) had CKD ≥ stage 3.
Between 2007 and 2016, proportions of initial HCQ
excess dosing declined from 40% to 36% per IBW-based
dosing (multivariable OR between 2007 and 2008 and
between 2015 and 2016, 0.85 (95% CI 0.76–0.95)) and
from 38% to 30% per ABW-based dosing (multivariable
OR, 0.76 (95% CI 0.68–0.86)) (Table 2). Correspond-
ingly, the median HCQ dose per IBW declined from
6.0 mg/kg to 5.7 mg/kg during the study period, and the
median HCQ dose per ABW declined from 4.4 mg/kg to
4.1 mg/kg (both p values < 0.01) (Fig. 1). Furthermore,
the proportions of initial prescribed daily dose categories
of HCQ changed over time, with a slightly lower propor-
tion of 400 mg per day prescribed in recent years and an
increase in the relative proportions of 100 mg, 300 mg,
and 500 mg doses, as shown in Fig. 2. These trends re-
main similar in our analyses that include subsequent
doses after initial doses (Additional file 1: Figure S1).
Furthermore, when we limited our analyses to those
with body weight measured within 1 year prior to index
date, our result did not change materially.
Using IBW-based recommended dose, 47% of women
and 7% of men had excess dosing, which resulted in a
multivariable OR of 12.52 (95% CI, 10.99–14.26). Using
the ABW-based recommended dose, 38% of women and
25% of men had excess dosing, which led to a multivari-
able OR of 1.98 (95% CI, 1.81–2.15) (Table 2). Age group
Table 1 Baseline characteristics of hydroxychloroquine incident users by time period
Time period of initial prescription
Characteristics 2007–2008 2009–2010 2011–2012 2013–2014 2015–2016 All
(n = 3297) (n = 4151) (n = 4927) (n = 4944) (n = 3614) (n = 20,933)
Sex (% female) 2617 (79) 3267 (79) 3822 (79) 3846 (78) 2751 (76) 16,303 (78)
Mean age, years (SD) 53.7 (15) 54.9 (15) 55.7 (15) 56.2 (15) 56.9 (15) 55.6 (15)
BMI, kg/m2 (mean +/− SD) 27.3 (6) 27.4 (6) 27.6 (6) 27.8 (6) 28.4 (6) 27.7 (6)
BMI category (%)
Underweight (BMI < 18.5) 81 (3) 89 (2) 95 (2) 90 (2) 68 (2) 424 (2)
Normal (BMI 18.5 – < 25) 1096 (37) 1371 (36) 1623 (36) 1553 (34) 1054 (31) 6697 (35)
Overweight (BMI 25 – < 30) 942 (32) 1274 (34) 1530 (34) 1527 (34) 1139 (33) 6412 (33)
Obese (BMI 30+) 815 (28) 1053 (28) 1271 (28) 1390 (31) 1157 (34) 5686 (30)
CKD (≥ stage 3) 213 (7) 344 (8) 366 (7) 366 (7) 283 (8) 1572 (8)
Tamoxifen use 26 (1) 47 (1) 66 (1) 69 (1) 54 (2) 262 (1)
Diabetes mellitus (%) 228 (7) 370 (9) 483 (10) 552 (11) 517 (14) 2150 (10)
Smoking status (% current smoker) 696 (22) 881 (22) 977 (20) 953 (20) 645 (18) 4152 (20)
Indication for HCQ (%)
RA/inflammatory arthritis 1745 (53) 2352 (57) 2794 (57) 2863 (58) 2001 (56) 11,749 (56)
SLE 459 (14) 462 (11) 481 (10) 415 (8) 283 (8) 2100 (10)
Systemic autoimmune rheumatic diseasea 117 (4) 156 (4) 183 (4) 174 (4) 148 (4) 778 (4)
Primary dermatologic disease 282 (9) 384 (9) 489 (10) 5142 (11) 486 (13) 2183 (10)
All other indications 700 (21) 797 (19) 980 (20) 950 (19) 696 (19) 4123 (20)
BMI body mass index, CKD chronic kidney disease, HCQ hydroxychloroquine, SLE systemic lupus erythematosus, RA rheumatoid arthritis
aSystemic autoimmune rheumatic disease category excludes SLE and RA
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was not associated with the risk of excess dosing in crude
comparison (Table 2); however, our sequential adjustment
of covariates in our model revealed that this null associ-
ation was confounded by the predominant presence of
young women among HCQ users. As such, when our
model was adjusted for female sex, older patients were
more likely to be prescribed HCQ doses exceeding either
recommendation in the adjusted models (multivariable
OR 1.23 (95% CI 1.15–1.32) for IBW and multivariable
OR 1.18 (95% CI 1.10–1.27) for ABW) (Table 2).
Proportions of initial HCQ excess dosing per the
IBW-based recommendation increased with increasing
Table 2 Initial hydroxychloroquine prescription dose in relation to dosing recommendations
Characteristics Dose > 6.5 mg/kg/day, ideal body weight (prior
recommendation)
Dose > 5 mg/kg/day, actual body weight (latest
recommendation)








Year of initial prescript
2007–2008 1099 (40) 1.00 (Reference) 1.00 (Reference) 1055 (38) 1.00 (Reference) 1.00 (Reference)
2009–2010 1406 (39) 0.98 (0.88–1.08) 1.00 (0.89–1.11) 1348 (38) 0.97 (0.88–1.08) 0.99 (0.89–1.11)
2011–2012 1597 (38) 0.92 0.83–1.02) 0.95 (0.85–1.05) 1519 (36) 0.91 (0.82–1.00) 0.92 0.83–1.03)
2013–2014 1511 (37) 0.88 (0.80–0.97) 0.90 (0.76–1.00) 1408 (35) 0.84 (0.76–0.93) 0.88 (0.79–0.99)
2015–2016 1073 (36) 0.84 (0.76–0.94) 0.85 (0.76–0.95) 901 (30) 0.70 (0.62–0.78) 0.76 (0.68–0.86)
Sex
Male 268 (7) 1.00 (Reference) 1.00 (Reference) 998 (25) 1.00 (Reference) 1.00 (Reference)
Female 6418 (47) 11.71 (10.30–13.32) 12.52 (10.99–14.26) 5233 (38) 1.76 (1.62–1.90) 1.98 (1.81–2.15)
Age
≤ 55 years 3647 (38) 1.00 (Reference) 1.00 (Reference) 3453 (36) 1.00 (Reference) 1.00 (Reference)
> 55 years 3039 (38) 1.00 (0.94–1.08) 1.23 (1.15–1.32) 2778 (35) 0.95 (0.89–1.01) 1.18 (1.10–1.27)
BMI (kg/m2)
Underweight (< 18.5) 104 (28) 0.74 (0.59–0.93) 0.66 (0.52–0.84) 176 (48) 0.82 (0.66–1.01) 0.78 (0.63–0.97)
Normal (18.5 – < 25) 2114 (35) 1.00 (Reference) 1.00 (Reference) 3215 (53) 1.00 (Reference) 1.00 (Reference)
Overweight (25 – < 30) 2134 (36) 1.07 (1.00–1.12) 1.28 (1.19–1.39) 2319 (39) 0.58 (0.54–0.63) 0.61 (0.57–0.66)
Obese (≥ 30) 2334 (44) 1.51 (1.40–1.63) 1.61 (1.49–1.75) 521 (10) 0.10 (0.09–0.11) 0.10 (0.09–0.11)
Smoking
Current smoker 1245 (36) 0.89 (0.83–0.96) 1.06 (0.98–1.16) 1294 (37) 1.10 (1.02–1.19) 1.03 (0.95–1.13)
Non-smoker 5426 (39) 1.00 (Reference) 1.00 (Reference) 4924 (35) 1.00 (Reference) 1.00 (Reference)
CKD
CKD stage > 3 516 (37) 0.97 (0.86–1.08) 0.88 (0.73–1.00) 429 (31) 0.81 (0.72–0.91) 0.87 (0.76–0.99)
No CKD 6170 (38.1) 1.00 (Reference) 1.00 (Reference) 5802 (36) 1.00 (Reference) 1.00 (Reference)
Diabetes
Yes 726 (38) 0.99 (0.90–1.09) 1.05 (0.94–1.17) 483 (25) 0.58 (0.52–0.65) 0.92 (0.81–1.03)
No 5960 (38) 1.00 (Reference) 1.00 (Reference) 5748 (37) 1.00 (Reference) 1.00 (Reference)
Tamoxifen use
Yes 113 (51) 1.67 (1.29–2.18) 1.16 (0.89–1.52) 94 (42) 1.32 (1.01–1.73) 1.16 (0.87–1.55)
No 6573 (38) 1.00 (Reference) 1.00 (Reference) 6137 (35) 1.00 (Reference) 1.00 (Reference)
Indication for HCQ
RA/inflammatory arthritis 3651 (36) 1.00 (Reference) 1.00 (Reference) 3491 (35) 1.00 (Reference) 1.00 (Reference)
SLE 628 (37) 1.03 (0.93–1.15) 0.84 (0.75–0.94) 590 (35) 1.04 (0.93–1.17) 0.87 (0.77–0.98)
SARD 287 (43) 1.34 (1.14–1.56) 1.07 (0.91–1.26) 272 (41) 1.29 (1.10–1.51) 1.09 (0.92–1.30)
Primary dermatologic disease 745 (41) 1.23 (1.11–1.36) 1.11 (0.99–1.25) 655 (36) 1.04 (0.95–1.15) 1.12 (0.99–1.26)
Other 1375 (41) 1.24 (1.14–1.34) 1.16 (1.06–1.27) 1223 (37) 1.10 (1.01–1.19) 1.14 (1.04–1.25)
BMI body mass index, CKD chronic kidney disease, SLE systemic lupus erythematosus, RA rheumatoid arthritis, SARD systemic autoimmune rheumatic disease
aMultivariable odds ratios are adjusted for age, sex, BMI, CKD, indication for hydroxychloroquine use, smoking, tamoxifen use, diabetes mellitus, and calendar year
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BMI (28%, 35%, 36%, and 44% in underweight, normal,
overweight, and obese categories, respectively) (Table 2).
These resulted in a multivariable OR of 1.61 (95% CI
1.49–1.75) for obese individuals versus individuals with
normal BMI (Table 2). In contrast, proportions of initial
HCQ excess dosing per ABW-based recommendation
decreased with increasing BMI (48%, 53%, 39%, and
10%, in underweight, normal, overweight, and obese
categories, respectively). These resulted in a multivari-
able OR of 0.10 (95% CI 0.09–0.11) among obese indi-
viduals versus individuals with normal BMI. Patients
with CKD had a lower risk of excess dosing by IBW (OR
0.88 (95% CI 0.73–1.00)) and by ABW (OR 0.87 (95% CI
0.76–0.99)).
Of 4276 (20%) subjects prescribed HCQ for 5 years or
more, the dose at 5 years of use remained largely unchanged
(median 400 mg/day). There was no difference in the pro-
portion of excess dosing between the initial dose and dose at
5 years. Of these subjects, 40% and 37% had excess dosing
by IBW for the initial dose and at 5 years (p= 0.40); 37% and
33% had excess dosing by ABW for the initial dose and at
5 years, respectively (p= 0.53).
Discussion
In this UK general population-based cohort, we identified
a modest decline in excess HCQ dosing in recent years.
While this decline may reflect increased awareness over
time of HCQ retinopathy risk, excess HCQ dosing
























































Fig. 1 Trends of incident hydroxychloroquine prescription dose per ideal body weight and actual body weight (2007–2016). Median and
inter-quartile ranges of incident hydroxychloroquine prescription dose, calculated per mg/kg of ideal body weight and per mg/kg of actual body









































Fig. 2 Incident hydroxychloroquine prescription dose trends. Proportion of incident hydroxychloroquine prescriptions in each dosing category
over time, between 2007 and 2016
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remains substantial over the past decade according to
prior IBW-based recommendations [2, 16, 17]. Applying
the latest ABW-based dosing recommendations [19] also
led to a considerable proportion of HCQ excess dosing,
including more than 50% among patients with normal
BMI. Overall, the excess dosing using either recommenda-
tion was more frequent among women, nearing 50% using
IBW and 38% using ABW criteria and was less frequent
among those with CKD. Moreover, proportions of excess
HCQ dosing did not change with long-term use of HCQ
(i.e., > 5 years). This further identifies a target population
with the potential for the largest cumulative HCQ expos-
ure and high risk of toxicity [18, 32–34].
To our knowledge, body weight and CKD are the pa-
tient factors most associated with risk of HCQ retinopathy
[18]. The presence of concomitant CKD was associated
with a slightly reduced risk of HCQ excess dosing. This
may reflect HCQ dose adjustment in some patients with
renal disease. Although there is no clear consensus on ap-
propriate dose reduction in renal insufficiency [35], CKD
was associated with more than doubling of the prevalence
of HCQ retinopathy in the recent KPNC study [18].
Regardless, in our study found more than 30% of CKD pa-
tients’ prescriptions still exceeded recommended doses
per the prior or latest guidelines, suggesting potentially
considerable room for improvement in this population.
BMI categories had an opposite impact on the risk of
excess dosing depending on which weight-based dosing
guideline was applied [16, 20]. Following the latest
ABW-based guideline, [19] more than 50% of individuals
with normal BMI would have had HCQ excess dosing,
compared to 10% of obese patients. In contrast, using
the prior IBW-based guideline [2, 16, 27], 44% of obese
patients and 37% of normal patients were exposed to ex-
cess dosing. This demonstrates the need for provider
awareness that the newer guidelines reclassify excess
dosing among a greater proportion of individuals with
normal body weight.
We also found a higher risk of excess dosing among
women, likely because HCQ 400 mg daily, which is the
most commonly used dose, falls into the excess ABW dose
range and IBW dose range among average-size women in
the UK [36–38]. These findings suggest that prescribers in
the UK may not have adjusted HCQ dosing based on IBW
as recommended by the previous UK RCO guideline [16],
particularly among women. It remains to be studied
whether the new ophthalmology dosing guidelines will im-
pact future prescribing patterns [20, 26]. Additionally, we
found that older patients had approximately 20% higher
risk of excess dosing than young patients (Table 2). As this
is the first report on the potential impact of aging on ex-
cess dosing and its mechanism is not immediately clear,
this finding awaits replication by future studies. It is also
unknown whether women or older individuals have an
increased risk of HCQ retinopathy, which could be corre-
lated with these dosing findings.
A major strength of our study is the use of a large gen-
eral population database to provide population-level data
on HCQ prescribing patterns and thus our findings are
likely to be generalizable. However, we were unable to
directly address specialty prescriptions, although we
found 68% of HCQ users were referred to rheumatolo-
gists and 9% to dermatologists around the time of first
HCQ prescription, and results were similar in these
users (data not shown). We focused on prescribed HCQ
doses rather than assessing actual dispensed prescrip-
tions or other measures of effective consumed dose of
HCQ as our goal for this study was to assess prescribing
patterns rather than patient adherence. Finally, our aim
was to describe the level of excess HCQ dosing accord-
ing to the previous and current guidelines; assessing the
risk of retinal toxicity was beyond the scope of the
current study. As the latest guideline change [20] has
been largely based on the single large recent KPNC
study [18], further data, particularly prospective evi-
dence, are needed to accurately establish the risk of
HCQ retinopathy and risk factors. We do not have suffi-
cient patient-level clinical data to determine the clinical
reasoning behind “excess” dosing. To that end, future
studies should also address whether reducing HCQ dos-
ing in many patients, following the existing ophthalmol-
ogy guidelines, will retain the efficacy of this medication.
Conclusions
In conclusion, this UK general population-based study
found that according to previous and latest ophthalmol-
ogy society guidelines, excess HCQ dosing is substantial,
despite a modest decline over recent years. Female pa-
tients more often receive an excess HCQ dose according
to these guidelines, and a similarly considerable propor-
tion of long-term HCQ users also experience excess
HCQ dosing. Over half of normal BMI individuals were
excess-dosed per the latest guidelines; however, BMI had
a noticeably opposite impact on the risk of excess dosing
between the prior and latest weight-based guidelines.
This implies the potential need to reduce dosing in
many patients but also calls for further research to es-
tablish unifying, evidence-based safe-dosing strategies,
balancing retinopathy risk and treatment efficacy.
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